Review Article: Ileal Bile Acid Transport ( IBAT ) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70666 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Matthew Peverelle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Monash Health, Melbourne, Australia. Hauptthemen laut MEDLINE: Cholestasis, Intrahepatic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
Background
Cholestatic liver diseases such as Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) cause significant morbidity and mortality. Chronic pruritus is common, debilitating, and impairs health‐related quality of life. Recently, pharmacological inhibition of the ileal bile acid transporter (IBAT) has emerged as a therapeutic target.
Aims
To review the current landscape of IBAT inhibitors, summarise emerging clinical data, discuss their role in the treatment of cholestatic liver diseases and future directions for their development and use.
Methods
This narrative review summarises current data on IBAT inhibitors, exploring their mechanisms, efficacy, and safety across ALGS, PFIC, PBC and PSC. References were identified through searches of PubMed from January 2000 to August 2025.
Results
In phase 2 and 3 trials involving paediatric patients with ALGS and PFIC, IBAT inhibitors (odevixibat and maralixibat) significantly reduced pruritus and serum bile acid concentrations. In post hoc analysis, responders demonstrated improved event‐free and transplant‐free survival compared to historic control cohorts. The phase 3 trial of linerixibat in PBC demonstrated an improvement in pruritus compared to placebo. Mild to moderate gastrointestinal side effects, most commonly diarrhoea and abdominal discomfort, are common with IBAT inhibition, particularly in PBC and PSC.
Conclusions
IBAT inhibitors represent the first upstream pharmacotherapy targeting enterohepatic bile acid recirculation and are effective at reducing pruritus in ALGS and PFIC. Their role in PBC and PSC is promising yet undefined. Long‐term studies are needed to assess effects on fibrosis progression, hepatocellular carcinoma risk and transplant‐free survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Monash Health, Melbourne, Australia.
- Institute of Liver Studies, King's College Hospital, London, UK.
ORCID-Profile: Matthew Peverelle, Samantha M A Campbell, Sital Shah, Deepak Joshi, Jeremy S Nayagam
Zitieren
APA
Peverelle, M., Campbell, S. M. A., Peverelle, J., Shah, S., Greener, K., Joshi, D., & Nayagam, J. S. (2026). Review Article: Ileal Bile Acid Transport ( IBAT ) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70666
Vancouver
Peverelle M, Campbell SMA, Peverelle J, Shah S, Greener K, Joshi D, et al. Review Article: Ileal Bile Acid Transport ( IBAT ) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70666
BibTeX
@article{Peverelle2026,
author = {Peverelle, Matthew and Campbell, Samantha M A and Peverelle, James and Shah, Sital and Greener, Kate and Joshi, Deepak and Nayagam, Jeremy S},
title = {Review Article: Ileal Bile Acid Transport ( IBAT ) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70666}
}
EUVIMED